Mayo Clinic Laboratory and pathology research roundup: June 6

By Samantha Rossi • June 6, 2023

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Utilizing mass spectrometry to detect and isotype monoclonal proteins in urine: Comparison to electrophoretic methods.

Matrix assisted laser desorption ionization time of flight mass spectrometry coupled to immune enrichment (MASS-FIX) as an alternative to serum immunofixation electrophoresis has demonstrated increased sensitivity in monoclonal protein (MP) detection with improved laboratory workflow. This study explored similar replacement of urine immunofixation electrophoresis (u-IFE) with urine MASS-FIX (u-MASS-FIX) by method comparison.

Read more.

Published to PubMed This Week

• Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome.
  Rheumatology
• Renal involvement in systemic sclerosis.
  Autoimmune reviews
• Clinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience.
  Human Pathology
• Evidence for angiotensin II as a naturally existing suppressor for the guanylyl cyclase a receptor and cyclic GMP generation.
  International Journal of Molecular Science
• MICon - A contamination detection workflow for NGS laboratories using microhaplotype locus and supervised learning.
  Journal of Molecular Diaganotics
• Use of the HEAR score for 30-day risk-stratification in emergency department patients.
  American Journal of Medicine
• Using AI to detect pain through facial expressions: A review.
  Bioengineering (Basel)
• Kappa free light chain drift prompts the need for a new upper limit of normal free light chain ratio to avoid an epidemic of kappa light chain monoclonal gammopathy of undermined significance.
  Journal of Applied Laboratory Medicine
• Functional and clinical characterization of variants of uncertain significance identifies a hotspot for inactivating missense variants in RAD51C.
  Cancer research
  

Samantha Rossi

Samantha Rossi is a Digital Marketing Manager at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.